Effect of Praziquantel Treatment during Pregnancy on Cytokine Responses to Schistosome Antigens: Results of a Randomized, Placebo-Controlled Trial

dc.contributor.authorTweyongyere, Robert
dc.contributor.authorMawa, Patrice A
dc.contributor.authorNgom-wegi, Sophy
dc.contributor.authorNdibazza, Juliet
dc.contributor.authorDuong, Trinh
dc.contributor.authorVennervald, Birgitte J.
dc.contributor.authorDunne, David W
dc.contributor.authorKatunguka-Rwakishaya, Eli
dc.contributor.authorElliott, Alison M.
dc.date.accessioned2018-07-25T12:32:02Z
dc.date.available2018-07-25T12:32:02Z
dc.date.issued2008
dc.description.abstractPraziquantel treatment of schistosomiasis boosts antischistosome responses, with type 2 helper T cell bias that may contribute to immunologically mediated killing and to protection against reinfection. Praziquantel treatment during pregnancy was recommended in 2002, but the immunological effects of the treatment had not been investigated. A cohort of 387 Schistosoma mansoni–infected women were recruited from a larger trial of deworming during pregnancy. Women were randomized to receive either praziquantel or placebo during pregnancy. Six weeks after delivery, all women received praziquantel. Cytokine responses to S. mansoni worm and egg antigens were measured in whole blood culture before and 6 weeks after each treatment. Schistosome-specific cytokine responses were suppressed during pregnancy. Praziquantel treatment during pregnancy caused significant boosts in interferon-_ (IFN-_), interleukin (IL)–2, IL-4, IL-5, IL-13, and IL-10 responses to schistosome worm antigen and in IFN-_, IL-5, and IL-13 responses to schistosome egg antigen, but these boosts were not as substantial as those seen for women treated after delivery. Pregnancy suppresses a potentially beneficial boost in cytokine responses associated with praziquantel treatment. Further studies are needed on the long-term effects that treatment of schistosomiasis during pregnancy have on morbidity and resistance to reinfection among treated women and their offspring. International Standard Randomized Controlled Trial Number for the parent study: ISRCTN32849447.en_US
dc.description.sponsorshipThe Wellcome Trust (grant 064693 to A.M.E.); Makerere University School of Graduate Studies; Danish Bilharziasis Laboratory.en_US
dc.identifier.otherDOI: 10.1086/593215
dc.identifier.urihttp://hdl.handle.net/20.500.12280/541
dc.language.isoenen_US
dc.publisherInfectious Diseases Society of Americaen_US
dc.relation.ispartofseriesThe Journal of Infectious Diseases;
dc.subjectPraziquantel treatmenten_US
dc.subjectPraziquantel treatment during pregnancyen_US
dc.subjectCytokine responses to schistosome antigensen_US
dc.titleEffect of Praziquantel Treatment during Pregnancy on Cytokine Responses to Schistosome Antigens: Results of a Randomized, Placebo-Controlled Trialen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ndibazza_Health_Article_2008.pdf
Size:
313.48 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: